Smith & Nephew gains from investments in wound care, emerging markets

Smith & Nephew ($SNN) has turned its eye toward wound care and emerging markets in recent months, and the strategy is paying off. The U.K. medical device company reported 4.4% growth in the second quarter, to $1.07 billion, thanks to healthy results in both areas. The company's performance matched the average of 12 analyst estimates, Bloomberg reports. Gains in international markets and negative pressure wound therapy helped offset a slow quarter in Smith & Nephew's orthopedic reconstruction business, CEO Olivier Bohuon noted in a statement. Last year, the company snatched up wound care company Healthpoint Biotherapeutics for $782 million. In May, Smith & Nephew invested in an Indian orthopedic trauma device company and launched a $300 million share buyback. More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.